AOD-9604 peptide: the fat-metabolism fragment guide

AOD-9604 is a modified 16-amino-acid fragment of human growth hormone, the 176-191 tail, developed as an anti-obesity drug. Across six placebo-controlled trials in about 900 people it looked as safe as placebo, but the efficacy was small: 2.6 kg lost on 1 mg a day by mouth versus 0.8 kg on placebo at 12 weeks, a gap that fell short of statistical significance in the company's primary analysis, and the largest, 24-week trial missed its endpoint, which ended development in 2007. It is not FDA-approved. In the US it cannot be compounded either: it has no USP monograph, is not part of any approved drug, and an FDA advisory committee voted 12 to 0 in December 2024 against adding it to the 503A bulks list (FDA committee minutes, 2024). It is prohibited in sport by WADA. This guide walks through what the trials measured, where the cartilage research is heading, and how to read the regulatory map.

Key takeaways#

• AOD-9604 is a synthetic 16-amino-acid fragment of the C-terminal region of human growth hormone (residues 176-191) with a stabilising tyrosine at the N-terminus.
• Across six randomised, double-blind, placebo-controlled trials in roughly 900 participants, the safety signal was indistinguishable from placebo and IGF-1 stayed flat.
• The largest 12-week Phase IIb produced an average weight reduction of 2.6 kg on 1 mg daily versus 0.8 kg on placebo, short of significance overall (the company reported p = 0.1) and significant only in women. The longer 24-week follow-up trial did not hit its endpoint and development was terminated in 2007.
• Mechanism is selective: lipolysis that, in mice, depends on the beta-3 adrenergic receptor in adipose tissue (AOD-9604 raises the receptor's expression rather than acting directly through it), with no hGH-receptor activation and no measurable change in glucose or insulin sensitivity.
• AOD-9604 is not approved by the FDA, EMA or Norway's DMP for any indication, and it cannot be compounded in the US: an FDA advisory committee voted 12 to 0 against adding it to the 503A bulks list in December 2024. It is on the WADA prohibited list at all times.

What AOD-9604 actually is#

AOD-9604 is a synthetic 16-amino-acid peptide fragment derived from the C-terminal domain of human growth hormone (amino acids 176-191) with a stabilizing tyrosine substitution at the N-terminus. It was originally developed by Metabolic Pharmaceuticals Ltd. in Australia during the 1990s as an "Anti-Obesity Drug," designed to harness growth hormone's lipolytic properties while avoiding broader metabolic and growth-promoting effects.

The naming creates persistent confusion. AOD-9604 and "HGH Fragment 176-191" are not interchangeable in a research context. HGH Fragment 176-191 has erroneously been presented as a lipolytic peptide fragment based on extrapolations of clinical data pertaining to AOD9604, a modified form of hGH frag 176-191. The tyrosine substitution matters: it is what gives AOD-9604 its stability profile and what the human trials actually measured.

How the mechanism is supposed to work#

The mechanism is what kept AOD-9604 in the conversation long after commercial development stalled. AOD-9604 mimics the lipolytic region of human growth hormone without binding to growth hormone receptors. The proposed downstream pathway is the classic lipolytic one: higher intracellular cyclic AMP, protein kinase A activation, and hormone-sensitive lipase breaking stored triglycerides into free fatty acids that can be released into the bloodstream and oxidized for energy. The receptor step is the part to read carefully. In obese mice AOD-9604 raised expression of the beta-3 adrenergic receptor, the main lipolytic receptor on fat cells, but the researchers concluded that its lipolytic action is not mediated directly through that receptor.

The beta-3 dependence is not theoretical. Heffernan et al. (2001), published in Endocrinology, tested AOD-9604 in beta-3 adrenergic receptor knockout mice. Animal studies have shown that when beta-3 adrenergic receptors were genetically removed, chronic AOD-9604 treatment produced no changes in weight or lipolysis, confirming the importance of this pathway. In a short acute experiment, though, AOD-9604 still raised energy expenditure and fat oxidation in the knockout mice. The same study found the peptide restores beta-3 receptor expression in obese mice toward levels seen in lean controls, which is why the authors read the receptor as an amplifier of the effect rather than its direct target.

What the molecule does not do is just as defining. Studies have shown AOD-9604 does not stimulate IGF-1, does not activate the hGH receptor, and does not measurably alter glucose tolerance. That separation is the entire point of the design.

What the human trials actually found#

The clinical paper trail is unusually thick for a non-approved peptide. A safety review in the Journal of Endocrinology and Metabolism by Stier, Vos and Kenley (2013) summarised six randomised, double-blind, placebo-controlled trials. The first three clinical trials were single-dose treatments (METAOD001 to METAOD003); the longest was a phase IIb clinical trial (METAOD006) with a four-week run-in phase, followed by a six-month treatment phase and a 30-day follow-up phase.

The two pivotal efficacy studies are worth naming:

METAOD005 was a Phase IIb randomised, double-blind, placebo-controlled study assessing efficacy, safety and tolerability of 12 weeks treatment with daily oral doses (1, 5, 10, 20 or 30 mg AOD9604) in 300 healthy clinically obese males and females of non-child-bearing potential, with a BMI of at least 35 kg/m².

METAOD006 was a Phase IIb randomised, double-blind, placebo-controlled study assessing efficacy of 24 weeks treatment with different doses of AOD9604 tablets (0.25 mg, 0.5 mg, 1 mg, or placebo) in 502 obese adults.

The 12-week trial generated the number that gets quoted everywhere. In a 12-week randomized clinical trial involving 300 obese adults, participants receiving 1 mg daily of AOD-9604 lost an average of 2.6 kg compared to 0.8 kg in the placebo group. That is about 1.8 kg more weight loss than placebo over 12 weeks (the trial measured body weight, not fat). The result was reported only in a 2005 conference abstract, and the company later said the 1 mg arm fell short of significance on its primary analysis (p = 0.1), reaching significance only in women (FDA briefing document, 2024).

That signal did not hold up. Despite completing six human clinical trials involving over 900 participants, AOD-9604 failed to achieve statistical significance in its largest Phase IIb trial and development was terminated in 2007. The peptide lacks regulatory approval from any major health authority worldwide.

The honest framing: AOD-9604 produced a small weight-loss signal in the 12-week study, significant only in women, and a clinically underwhelming result in the longer trial that would have decided commercial fate.

How the safety profile reads#

The safety database is the most defensible part of the AOD-9604 story. Across the six trials in roughly 900 participants, no significant changes or obvious trends in the OGTT in any treatment group were observed, suggesting that AOD9604 supplementation does not deteriorate glucose control or induce insulin resistance. In contrast, treatment with AOD9604 seemed to have a positive effect in subjects with impaired glucose tolerance.

Preliminary evidence on antibody formation was equally reassuring. The research, published in the Journal of Endocrinology and Metabolism, found that the peptide had no effect on serum IGF-1 levels, no negative effect on carbohydrate metabolism, and no anti-AOD-9604 antibodies were detected in any patients.

Two caveats matter. First, the longest trial ran six months. There is no public long-term human safety data beyond that window. Second, "indistinguishable from placebo on safety" is not the same as "indistinguishable from placebo on efficacy", and conflating the two is the most common error in clinic marketing copy.

How AOD-9604 compares to GLP-1 medications and HGH#

The comparison most readers actually want is the one the data does not flatter. Modern GLP-1 and dual-incretin medications are associated with double-digit percentage weight reductions in their pivotal trials. AOD-9604's best human result is approximately 1.8 kg of additional weight loss over 12 weeks. They are not in the same efficacy tier and should not be positioned as substitutes.

Against full-length human growth hormone, the comparison is more interesting. In the trial safety summary, AOD-9604 did not produce any of the adverse effects associated with full-length growth hormone therapy: no rise in IGF-1, no impaired glucose tolerance and no insulin resistance across six trials. That selectivity is the molecule's actual selling point: not "more weight loss than hGH" but "the lipolytic signal isolated from the rest of the cascade".

Compared with cagrilintide or retatrutide, which work through appetite and incretin pathways, AOD-9604 is appetite-neutral. It does not change how much food a person wants to eat. Whether that is an advantage or a limitation depends entirely on what is driving the individual's weight trajectory.

For protocol design and conversion math across peptide classes, the peptide calculator handles the unit work; how Klarovel works explains where the protocol layer sits.

The cartilage research: a second life worth watching#

After commercial obesity development stalled, AOD-9604 reappeared in regenerative orthopaedics. The most cited preclinical signal comes from Kwon and Park (2015), in Annals of Clinical and Laboratory Science. The study investigated AOD9604 intra-articular injections with or without hyaluronic acid in a collagenase-induced knee osteoarthritis rabbit model. Intra-articular AOD9604 injections using ultrasound guidance enhanced cartilage regeneration, and combined AOD9604 and HA injections were more effective than HA or AOD9604 injections alone.

Preclinical data points to chondrocyte proliferation and type II collagen synthesis as plausible mechanisms, distinct from the lipolytic pathway. In a rabbit study using a model of knee osteoarthritis, intra-articular injections of AOD9604 enhanced cartilage regeneration. The peptide is now grouped alongside other compounds being studied for joint repair and bone health, though this research is still in early stages and has not been validated in large human trials.

This is a research signal, not a clinical recommendation. There is no published large-scale human osteoarthritis trial that would justify treating AOD-9604 as a joint therapy.

Dosing, administration, and what the literature actually says#

The trial-derived ranges below describe what the published studies measured. Klarovel's curated reference range for subcutaneous use starts at 250 mcg once daily for someone new to peptides and reaches 500 mcg to 1 mg daily for experienced users, with 1 mg as the ceiling. Neither is a prescription.

The Phase IIb trials tested oral doses ranging from 0.25 mg to 30 mg daily. The 1 mg daily oral dose is the figure most commonly referenced in the efficacy literature. Subcutaneous dosing in clinical settings has been described in the 250 to 500 microgram per day range, but this comes from clinical practice reports rather than registration-grade trials. Across all six trials, oral doses ran from 0.25 mg to 54 mg a day, taken once daily, and the two intravenous studies used single infusions of 25 to 400 mcg per kg of body weight (Stier, Vos and Kenley, 2013). Starting at lower doses allows assessment of individual tolerance and response before potentially increasing the dose.

The published trial summaries do not specify morning or fasted dosing; that convention comes from clinic protocols. Cycle lengths in the published research ran 12 to 24 weeks. There is no robust human data on cycling on/off patterns; that is folklore from clinic protocols, not from the trials.

For protocol planning and cross-checking units against the published doses, see the peptide calculator. The disclosures page explains how Klarovel's curation layer is structured and its research-only positioning.

The honest summary#

AOD-9604 has been studied more than most peptides in the weight-metabolism conversation. The mechanism is selective and well characterised, the safety database is unusually long, and the efficacy is real but modest. Until comprehensive efficacy data becomes available, AOD-9604 remains primarily a research tool rather than a validated therapeutic intervention.

The cartilage signal is the more interesting frontier. Preliminary evidence from animal models suggests a regenerative role distinct from the lipolytic mechanism, and that line of research is still active.

For anyone weighing AOD-9604 against modern incretin therapies on weight loss alone, the data does not support equivalence, a contrast the broader guide to peptides for weight loss lays out across the whole class. For anyone interested in the molecule for its actual differentiator, isolated lipolysis without IGF-1 elevation, the case is more defensible but still unproven in approved use.

Direct comparisons: AOD-9604 vs tirzepatide.

Where Klarovel fits#

Klarovel does not sell, source or fulfil AOD-9604 or any other peptide. What Klarovel adds is the protocol structuring, dose-conversion tooling, and source-cited education that turns a peptide name into a defensible plan.

If AOD-9604 belongs in a personal research framework, the work is in matching the mechanism to the actual goal, not in chasing the marketing arc. Create an account to build a structured protocol, or run the numbers first with the peptide calculator.